Literature DB >> 24371077

GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.

Klára Grantz Šašková1, Milan Kozíšek, Kirsten Stray, Dorien de Jong, Pavlína Rezáová, Jirí Brynda, Noortje M van Maarseveen, Monique Nijhuis, Tomáš Cihlár, Jan Konvalinka.   

Abstract

Insertions in the protease (PR) region of human immunodeficiency virus (HIV) represent an interesting mechanism of antiviral resistance against HIV PR inhibitors (PIs). Here, we demonstrate the improved ability of a phosphonate-containing experimental HIV PI, GS-8374, relative to that of other PIs, to effectively inhibit patient-derived recombinant HIV strains bearing PR insertions and numerous other mutations. We correlate enzyme inhibition with the catalytic activities of corresponding recombinant PRs in vitro and provide a biochemical and structural analysis of the PR-inhibitor complex.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371077      PMCID: PMC3957959          DOI: 10.1128/JVI.02688-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene.

Authors:  C Amiel; C Charpentier; N Désiré; P Bonnard; M-G Lebrette; L Weiss; G Pialoux; V Schneider
Journal:  HIV Med       Date:  2010-08-15       Impact factor: 3.180

2.  Amino acid insertions at position 35 of HIV-1 protease interfere with virus replication without modifying antiviral drug susceptibility.

Authors:  Stefania Paolucci; Fausto Baldanti; Luca Dossena; Giuseppe Gerna
Journal:  Antiviral Res       Date:  2006-01-20       Impact factor: 5.970

3.  Detection of the protease codon 35 amino acid insertion in sequences from treatment-naïve HIV-1 subtype C infected individuals in the Central Region of Portugal.

Authors:  João Pereira-Vaz; Vitor Duque; Luís Trindade; José Saraiva-da-Cunha; António Meliço-Silvestre
Journal:  J Clin Virol       Date:  2009-07-22       Impact factor: 3.168

4.  Molecular epidemiology and divergence of HIV type 1 protease codon 35 inserted strains among treatment-naive patients in Hong Kong.

Authors:  J H K Chen; K H Wong; K C Chan; H Y Lam; K Y Yuen; V C C Cheng; W C Yam
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

5.  A first case of protease codon 35 amino acid insertion in a HIV-1 subtype B sequence detected in the Bauru region, state of São Paulo, Brazil: case report.

Authors:  Rejane Maria Tommasini Grotto; Sílvia Maria Corvino; Lilian da Silva Reis Munhoz; Cibele Gomes Ghedini; Maria Inês de Moura Campos Pardini
Journal:  Rev Soc Bras Med Trop       Date:  2011 May-Jun       Impact factor: 1.581

6.  In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile.

Authors:  Christian Callebaut; Kirsten Stray; Luong Tsai; Matt Williams; Zheng-Yu Yang; Carina Cannizzaro; Stephanie A Leavitt; Xiaohong Liu; Kelly Wang; Bernard P Murray; Andrew Mulato; Marcos Hatada; Tina Priskich; Neil Parkin; Swami Swaminathan; William Lee; Gong-Xin He; Lianhong Xu; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

7.  Ninety-nine is not enough: molecular characterization of inhibitor-resistant human immunodeficiency virus type 1 protease mutants with insertions in the flap region.

Authors:  Milan Kozísek; Klára Grantz Sasková; Pavlína Rezácová; Jirí Brynda; Noortje M van Maarseveen; Dorien De Jong; Charles A Boucher; Ron M Kagan; Monique Nijhuis; Jan Konvalinka
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

Review 8.  Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.

Authors:  Luis Menéndez-Arias
Journal:  Antiviral Res       Date:  2013-02-08       Impact factor: 5.970

9.  Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

Authors:  Milan Kozísek; Jenelle Bray; Pavlína Rezácová; Klára Sasková; Jirí Brynda; Jana Pokorná; Fabrizio Mammano; Lubomír Rulísek; Jan Konvalinka
Journal:  J Mol Biol       Date:  2007-10-03       Impact factor: 5.469

10.  In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Authors:  Richard Hazen; Robert Harvey; Robert Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vincente Samano; Eric Furfine; Andrew Spaltenstein; Michael Hale; Roger Tung; Marty St Clair; Mary Hanlon; Lawrence Boone
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

View more
  3 in total

Review 1.  Highly resistant HIV-1 proteases and strategies for their inhibition.

Authors:  Irene T Weber; Daniel W Kneller; Andres Wong-Sam
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

2.  Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.

Authors:  Yuqi Yu; Jinan Wang; Qiang Shao; Jiye Shi; Weiliang Zhu
Journal:  Sci Rep       Date:  2015-05-27       Impact factor: 4.379

3.  Effect of polarization on HIV-1protease and fluoro-substituted inhibitors binding energies by large scale molecular dynamics simulations.

Authors:  Li L Duan; T Zhu; Yu C Li; Qing G Zhang; John Z H Zhang
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.